Article Information
History
- September 11, 2023.
Article Versions
- Version 1 (July 16, 2023 - 09:28).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Affan Shoukat1,
- Elaheh Abdollahi1,2,
- Alison P. Galvani2,
- Scott A. Halperin3,
- Joanne M. Langley3 and
- Seyed M. Moghadas1,*
- 1Agent-Based Modelling Laboratory, York University, Toronto, Ontario, Canada
- 2Center for Infectious Disease Modeling and Analysis (CIDMA), Yale School of Public Health, New Haven, CT, USA
- 3Canadian Center for Vaccinology, Dalhousie University, IWK Health and Nova Scotia Health, Halifax, Nova Scotia, Canada
- ↵*Corresponding author:
Seyed M. Moghadas (moghadas{at}yorku.ca)
Posted September 11, 2023.
Cost-Effectiveness Analysis of Nirsevimab and RSVpreF Vaccine Prevention Strategies for Respiratory Syncytial Virus Disease in infants: A Canadian Immunisation Research Network (CIRN) Study
